Page 6 - Thomas Eldered News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Article content Recipharm AB and Moderna Inc have finalized a deal under which the Sweden-based company will help manufacture Moderna’s COVID-19 vaccine outside the United States potentially starting early next year, the companies said on Wednesday. Recipharm last month said it had agreed to a preliminary deal with Moderna to fill and seal the packaging for the vaccine, which has recently been authorized for emergency use in the United States. We apologize, but this video has failed to load. Try refreshing your browser, or Sweden's Recipharm to help make Moderna's COVID-19 vaccine outside ...

Offer document regarding Roar BidCo AB's cash offer to the shareholders and Holders of Convertible Bonds in Recipharm AB (publ) made public: EQT Tel: + 46 8 506 55 334, email: press@eqtpartners.com For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares, or, in respect of the Convertible Bonds, Lucid Issuer Services Limited: Lucid Issuer Services Limited Attention: Owen Morris Email: recipharm@lucid-is.com The information in this press release was submitted for publication by Roar BidCo (contact details to EQT Press Office ...

By Reuters Staff 2 Min Read STOCKHOLM (Reuters) -Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at 23.6 billion Swedish crowns ($2.80 billion). Recipharm, a contract development and manufacturing organisation (CDMO) for the pharma industry, recently signed a preliminary deal with Moderna Inc to fill and seal the packaging for the U.S drugmaker’s new COVID-19 vaccine. EQT said it was bidding 220 crowns per Recipharm share, a 22.9% premium to Recipharm’s closing price on Friday. “Recipharm has generated strong gro...

EQT Offers to Buy Recipharm of Sweden in $2.1 Billion Deal Bloomberg 12/14/2020 Charles Daly © Bloomberg Recipharm shares rose as much as 23% to 220.20 kronor, near the bid price, in Stockholm Monday morning. (Bloomberg) -- Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions. EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract...